TOLERX, INC. Patent applications |
Patent application number | Title | Published |
20130030156 | ANTI-ILT5 ANTIBODIES AND ILT5-BINDING ANTIBODY FRAGMENTS - Disclosed herein are antibodies and ILT5-binding fragments thereof that specifically bind to ILT5, e.g., human ILT5 (hILT5), and pharmaceutical compositions comprising such ILT5-binding antibodies and ILT5-binding fragments thereof. | 01-31-2013 |
20110034675 | Ilt3 Binding Molecules And Uses Therefor - The present invention provides binding molecules that specifically bind to ILT3, e.g., human ILT3 (hILT3), on antigen presenting cells, such as for example, monocytes, macrophages and dendritic cells (DC), e.g., monocyte-derived dendritic cells (MDDC). The binding molecules of the invention are characterized by binding to hILT3 with high affinity and downmodulating immune responses in vitro, e.g., downmodulating alloimmune responses; the production of inflammatory cytokines by dendritic cells, e.g., monocyte-derived dendritic cells (MDDC); the upregulation of costimulatory molecules by DC, e.g., MDDC; and/or calcium flux in monocytes. In addition, the binding molecules upregulate the expression of inhibitory receptors on dendritic cells, e.g., immature dendritic cells. Surprisingly, these same binding molecules which downmodulate immune responses in vitro, are immunostimulatory in vivo. | 02-10-2011 |
20100056759 | Methods and Compositions for Efficient Removal of Protein A from Binding Molecule Preparations - The present invention features methods for reducing protein A contamination in a binding molecule preparation, e.g., a therapeutic binding molecule preparation, comprising residual protein A, or fragments thereof. | 03-04-2010 |
20090318357 | Molecules Preferentially Associated with Effector T Cells or Regulatory T Cells and Methods of Their Use - The present invention is based, at least in part, on the finding that certain molecules are preferentially associated with effector T cells or regulatory T cells. Accordingly, immune responses by one or the other subset of cells can be preferentially modulated. The invention pertains, e.g., to methods of modulating (e.g., up- or down-modulating), the balance between the activation of regulatory T cells and effector T cells leading to modulation of immune responses and to compositions useful in modulating those responses. The invention also pertains to methods useful in diagnosing, treating, or preventing conditions that would benefit from modulating effector T cell function relative to regulatory T cell function or from modulating regulatory T cell function relative to effector T cell function in a subject. The subject methods and compositions are especially useful in the diagnosis, treatment or prevention of conditions characterized by a too-vigorous effector T cell response to antigens associated with the condition, in the diagnosis, treatment or prevention of conditions characterized by a weak effector T cell response, in the diagnosis, treatment or prevention of conditions characterized by a too-vigorous regulatory T cell response, or in the diagnosis, treatment, or prevention of conditions characterized by a weak regulatory T cell response. | 12-24-2009 |
20090136494 | Combination therapies employing GITR binding molecules - The present invention provides combination therapies that employ a GITR binding molecule in combination with one or more additional agents. | 05-28-2009 |